← All trials
NCT05780281
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2020
- Primary completion
- Jun 9, 2021
- Completion date
- Oct 4, 2022
- First posted
- Mar 22, 2023
- Last posted
- Dec 27, 2023
- Enrollment
- 367
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- AIDS Clinical Trials GroupCollaborator
- Cardiothoracic Surgical Trials NetworkCollaborator
- GlaxoSmithKlineCollaborator
- University of CopenhagenOverall official - principal investigator
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Collaborator
- University of New South WalesCollaborator
- Medical Research CouncilCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of CopenhagenCollaborator
- University of MinnesotaCollaborator
- Department of Veteran AffairsCollaborator
- Vir Biotechnology, Inc.Collaborator
- Department of Veteran AffairsCollaborator
- University of MinnesotaOfficial
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of CopenhagenOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.